Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
  • Publication number: 20140255990
    Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 11, 2014
    Applicant: Arizona Board of Regents
    Inventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
  • Patent number: 8829177
    Abstract: We describe methods and DNA constructs/engineered mammalian promoters to enhance native promoter activity while retaining inherent regulation by inserting multi-copy response elements (REs) into non-adjacent locations. Multiple copies of REs are clustered in a group forming a transcription factor response element segment. The segment is at least duplicated in tandem upstream of the ATG start codon. Spacers of 0.2-0.7 kilo base pairs are introduced between the two segments and smaller spacers of about between 9-15 bp are introduced between the copies of REs within a segment.
    Type: Grant
    Filed: June 5, 2010
    Date of Patent: September 9, 2014
    Assignee: The General Hospital Corporation
    Inventors: David B. Rhoads, Jianmin Huang, Lynne L. Levitsky
  • Patent number: 8829272
    Abstract: The present invention relates generally to methods and transcriptional control sequences suitable for effecting expression of a nucleotide sequence of interest in a plant. More particularly, the present invention relates to methods and transcriptional control sequences suitable for directing specific or preferential expression of a nucleotide sequence of interest in a plant seed. Of particular interest as a transcriptional control sequence in this invention is the promoter PR602 (SEQ ID NO: 1) found in the 5?-untranslated region of the rice END1-like gene and isolated from a rice panicle library.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: September 9, 2014
    Assignees: Adelaide Research & Innovation Pty Ltd, Grains Research & Development Corporation
    Inventors: Sergiy Lopato, Ming Li
  • Patent number: 8829176
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: September 9, 2014
    Assignee: Genzyme Corporation
    Inventors: Scott D. Estes, Weiqun Zhang
  • Patent number: 8828961
    Abstract: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: September 9, 2014
    Assignee: Harrisvaccines
    Inventors: John Dustin Loy, Lyric Colleen Bartholomay, Delbert Linn Harris, Ed Scura, Kurt Iver Kamrud
  • Patent number: 8828959
    Abstract: A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i).
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: September 9, 2014
    Assignee: Gene Signal International SA
    Inventor: Salman Al-Mahmood
  • Patent number: 8829173
    Abstract: This disclosure provides recombinant replication competent retroviral vectors having increased stability. The disclosure further relates compositions and uses of such vectors in the treatment of disease and disorders.
    Type: Grant
    Filed: March 26, 2011
    Date of Patent: September 9, 2014
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Patent number: 8828962
    Abstract: No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of ?-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: September 9, 2014
    Assignee: Xiangxue Group (Hong Kong) Company Limited
    Inventors: Bojian Zheng, Hongyan Sui, Yongping Lin
  • Patent number: 8828658
    Abstract: The invention provides methods, materials and systems of regulating association between proteins of interest using light. In an aspect, the invention takes advantage of the ability of phytochromes to change conformation upon exposure to appropriate light conditions, and to bind in a conformation-dependent manner to cognate proteins called phytochrome-interacting factors. The invention comprises a method of regulating interaction between a first protein of interest and second protein within a cell by light. Such a method optionally comprises providing in the cell (1) a first protein construct which comprises the first protein, a phytochrome domain (PHD), and (2) providing in the cell a second protein construct which comprises the second protein and a phytochrome domain-interacting peptide (PIP) that can bind selectively to the Pfr state, but not to the Pr state, of the phytochrome domain.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: September 9, 2014
    Assignee: The Regents of the University of California
    Inventors: Christopher A. Voigt, Anselm Levskaya, Wendell Lim
  • Publication number: 20140248701
    Abstract: Isolated polynucleotides comprising a DCX mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.
    Type: Application
    Filed: January 23, 2014
    Publication date: September 4, 2014
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra, Charles de Leeuw
  • Publication number: 20140250546
    Abstract: The invention relates to efficient, high-throughput methods, systems, and DNA constructs for identification and isolation of terminator sequences causing enhanced transcription. The invention further relates to terminator sequences isolated with such methods and their use for enhancing gene expression.
    Type: Application
    Filed: July 20, 2012
    Publication date: September 4, 2014
    Applicant: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Julia Verena Hartig, Alrun Nora Burgmeier, Josef Martin Kuhn, Linda Patricia Loyall, Elke Duwenig
  • Publication number: 20140249303
    Abstract: The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 4, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Steven R. Brant, Amir Karban, Franklin Nouvet, Theodore M. Bayless, James J. Potter, Esteban Mezey, Toshihiko Okazaki
  • Publication number: 20140248309
    Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.
    Type: Application
    Filed: February 20, 2014
    Publication date: September 4, 2014
    Applicant: Government of the U.S.A, as represented by the Secretary, Dept. of Health & Human S
    Inventors: DENNIS J. KOPECKO, MANUEL OSORIO, SIBA BHATTACHARYYA, CHANDRAKANT P. GIRI, MILAN BLAKE
  • Patent number: 8822427
    Abstract: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: September 2, 2014
    Assignee: Harrisvaccines
    Inventors: John Dustin Loy, Lyric Colleen Bartholomay, Delbert Linn Harris, Ed Scura, Kurt Iver Kamrud
  • Patent number: 8822759
    Abstract: The present invention relates to transcriptional control sequences derived from GL9 genes, wherein the transcriptional control sequences direct specific or preferential expression of an operably connected nucleotide sequence of interest in one or more parts of a plant seed.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 2, 2014
    Assignee: Australian Centre for Plant Functional Genomics Pty. Ltd.
    Inventors: Sergiy Lopato, Nataliya Kovalchuk
  • Patent number: 8822666
    Abstract: The present invention relates to novel hybrid promoters comprising a caulimovirus promoter operably linked to one or more of an EF1?, Act8, Act2 or Act11 promoter. The present invention also relates to novel DNA constructs comprising at least one expression cassette which comprises the hybrid promoter thereof. The present invention further relates to transgenic plants/seeds comprising such DNA constructs.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Monsanto Technology LLC
    Inventors: Karen L. Fincher, Stanislaw Flasinski, Jack Q. Wilkinson
  • Publication number: 20140243203
    Abstract: Compositions and methods relating to the use of sulfonylurea-mediated control of gene expression are provided. Compositions include sulfonylurea responsive chemical switches wherein the gene expression is regulated by a sulfonylurea compound. Compositions also include polynucleotides encoding the polypeptides as well as constructs, vectors, prokaryotic and eukaryotic cells, and eukaryotic organisms including plants and seeds comprising the polynucleotide, and/or produced by the methods. Also provided are methods to regulate expression of a polynucleotide of interest in a cell or organism, and methods to modify a genome, including in a plant or plant cell.
    Type: Application
    Filed: February 27, 2014
    Publication date: August 28, 2014
    Applicants: PIONEER HI-BRED INTERNATIONAL INC, E I DU PONT DE NEMOURS AND COMPANY
    Inventors: JIN FANG, William Gordon-Kamm, Keith Lowe, Kevin E. McBride, Brian McGonigle, Carl Simmons
  • Publication number: 20140242636
    Abstract: A method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line comprising an expression construct comprising a regulatable promoter and a nucleic acid molecule encoding a POI under the transcriptional control of said promoter, comprising the steps a) cultivating the cell line with a basal carbon source repressing the promoter, b) cultivating the cell line with a limited amount of a supplemental carbon source de-repressing the promoter to induce production of the POI at a transcription rate of at least 15% as compared to the native pGAP promoter, and c) producing and recovering the POI; and further an isolated regulatable promoter and a respective expression system.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 28, 2014
    Applicant: LONZA LTD.
    Inventors: Diethard Mattanovich, Brigitte Gasser, Michael Maurer, Roland Prielhofer, Joachim Klein, Jana Wenger
  • Patent number: 8816059
    Abstract: The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-?N, and inhibitors of CPE-?N and compositions thereof.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: August 26, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yoke-peng Loh, Niamh X. Cawley, Saravana Radha Krishna Murthy, Terence K. Lee
  • Patent number: 8815819
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: August 26, 2014
    Assignee: Coda Therapeutics, Inc.
    Inventors: Wilda Laux, Colin Richard Green
  • Patent number: 8816152
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: August 26, 2014
    Assignee: Monsanto Technology LLC
    Inventors: Tedd D. Elich, Philip N. Benfey, Ai-Jiuan Wu, David A. Orlando, Ian Davis
  • Patent number: 8816061
    Abstract: A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 26, 2014
    Assignee: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University
    Inventors: James C. Carrington, Edwards Allen
  • Patent number: 8815779
    Abstract: This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: August 26, 2014
    Assignee: SwitchGear Genomics, Inc.
    Inventors: Shelley Force Aldred, Nathan D. Trinklein, Michael Rose, Patrick Collins
  • Patent number: 8816056
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: August 26, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Patent number: 8815568
    Abstract: The invention provides eukaryotic unicellular algae engineered to express a nucleosome alteration protein fused to a protein with affinity to the DNA binding site acting in coordination. An example is a LexA-p300 fusion protein, where the p300 is derived from Chlamydomonas. The LexA binding domain guides the p300 to the binding site and the p300 loosens the nucleosome structure by acetylating histones within proximity of the transgene, thus remodeling the local chromatin structure to allow for high-level expression.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 26, 2014
    Assignee: Synaptic Research, LLC
    Inventors: George Oyler, Julian Rosenberg
  • Patent number: 8816153
    Abstract: Recombinant DNA constructs, for use in plants and plant cells, have site-specific recombination sites that allow assessing phenotypes and modes of action by over expression or suppression of endogenous genes. In an aspect, a single DNA construct can be switched between over expression and suppression by the action of a recombinase such as the Cre recombinase on constructs having lox recombination sites. Other useful recombination systems include the Flp/frt system, the R/Rs system, the Dre/rox system, and the GIN/gix system.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: August 26, 2014
    Assignee: Monsanto Technology LLC
    Inventors: Larry A. Gilbertson, Shihshieh Huang, Thomas Malvar
  • Patent number: 8816060
    Abstract: The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: August 26, 2014
    Assignee: Rockefeller University
    Inventors: Thomas H. Tuschl, Markus Landthaler, Gunter Meister, Sebastien Pfeffer
  • Publication number: 20140237685
    Abstract: Methods and compositions that affect grain shape, width, and yield in rice are disclosed. Methods of transgenic modulation and marker-assisted breeding methods improve grain length to width ratio and grain yield in rice. Down-regulation of OsSPL16 in rice resulted in increased grain quality.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 21, 2014
    Inventors: Xiangdong Fu, Shaokui Wang, Kun Wu, Guiquan Zhang, Ruizhen Zeng
  • Publication number: 20140237682
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Application
    Filed: July 18, 2012
    Publication date: August 21, 2014
    Inventors: Tedd D. Elich, Philip N. Benfey, Ian Davis
  • Patent number: 8809017
    Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 19, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
  • Patent number: 8809289
    Abstract: A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: August 19, 2014
    Assignees: Saitama Medical University, RNAi Co., Ltd.
    Inventors: Satoshi Inoue, Ikeda Kazuhiro
  • Patent number: 8809628
    Abstract: The present invention provides non-coding regulatory element polynucleotide molecules isolated from the S-adenosyl methionine synthetase (SAMS3) gene of Arabidopsis thaliana and useful for expressing transgenes in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the Arabidopsis thaliana regulatory polynucleotide sequences, and methods for preparing and using the same.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: August 19, 2014
    Assignee: Monsanto Technology LLC
    Inventors: Wei Wu, Qi Wang, Michael Edgerton, Kim Beazley, Jill Deikman, Michael W. Petersen, Bei Zhang
  • Patent number: 8809626
    Abstract: Trichome specific plant promoters are provided herein. Also provided are transgenic cells and organisms, especially plant cell and plants, comprising an trichome specific promoter and methods for expressing nucleic acid sequences in cells and organisms using trichome specific promoters.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: August 19, 2014
    Assignee: KeyGene N.V.
    Inventors: Petronella Martina Bleeker, Christianus Cornelis Nicolaas Van Schie, Paul Johan Diergaarde, Robert Cornelis Schuurink, Michel Albertus Haring, Michiel Theodoor Jan De Both
  • Publication number: 20140230093
    Abstract: The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants. Methods for expressing polynucleotides in a plant cell, plant tissue, or plants using the regulatory polynucleotide molecules disclosed herein are also provided.
    Type: Application
    Filed: July 18, 2012
    Publication date: August 14, 2014
    Inventors: Tedd D. Elich, Philip N. Benfey, Ian Davis, David A. Orlando
  • Patent number: 8802921
    Abstract: A method for producing a transgenic plant includes providing a nucleic acid molecule comprising at least two regions of nucleic acid sequence that lack sequence homology with genomic DNA of the plant cell, and at least two zinc finger nuclease recognition sites, wherein the at least two regions of nucleic acid sequence that lack sequence homology with genomic DNA of the plant cell flank the at least two zinc finger nuclease recognition sites. A plant cell or tissue having the nucleic acid molecule stably integrated into the genome of the plant cell is transformed. A plant is regenerated from the plant cell. Transgenic plants are produced by the method. Seeds are produced by the transgenic plants.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: August 12, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: William M. Ainley, Ryan C. Blue, Michael G. Murray, David Corbin, Rebecca R. Miles, Steven R. Webb
  • Patent number: 8802928
    Abstract: The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a Yield Enhancing Protein (YEP). The YEP is selected from a Nucleosome Assembly Protein 1-like polypeptide (NAP1-like), a Like Sm polypeptide (Lsm protein), a truncated Cyclin H (CycHTr) polypeptide, a Remorin polypeptide, and a DREB protein. The present invention also concerns plants having modulated expression of a nucleic acid encoding such a YEP, which plants have enhanced yield-related traits relative to control plants. The invention also provides hitherto unknown YEP-encoding nucleic acids, and constructs comprising the same, useful in performing the methods of the invention.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: August 12, 2014
    Assignee: BASF Plant Science GmbH
    Inventors: Ana Isabel Sanz Molinero, Valerie Frankard, Yves Hatzfeld, Christophe Reuzeau
  • Patent number: 8802080
    Abstract: Disclosed are improved recombinant adeno-associated viral (rAAV) vectors having mutations in one or more capsid proteins. Exemplary vectors are provided that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations that comprise them useful in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 12, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Kenneth H. Warrington, Shaun R. Opie, Nicholas Muzyczka
  • Patent number: 8802645
    Abstract: The invention provides two types of oligonucleotides for treating an inflammatory disorder: an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a and an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RAcP. The invention further provides the use of said oligonucleotides for preventing or treating an inflammatory disorder.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 12, 2014
    Assignees: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus, Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Joseph Stephan Verbeek, Aliye Seda Ylmaz-Elis
  • Patent number: 8802648
    Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: August 12, 2014
    Inventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale
  • Publication number: 20140220632
    Abstract: The present disclosure generally provides non-naturally-occurring polynucleotide sequences that facilitate high-level expression of one or more gene products (e.g., polypeptides, RNA) of interest in Neisseria meningitidis. Methods of use of such sequences, e.g., use in vaccine production, are also provided.
    Type: Application
    Filed: August 30, 2012
    Publication date: August 7, 2014
    Applicant: Children's Hospital & Research Center Oakland
    Inventor: Rolando Pajon Feyt
  • Patent number: 8796444
    Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: August 5, 2014
    Assignees: City of Hope, Integrated DNA Technologies, Inc.
    Inventors: John J. Rossi, Mark A. Behlke, Dongho Kim
  • Patent number: 8796507
    Abstract: The present invention relates to promoters that enable gene expression which is both specific to the endosperm and early during the development of the endosperm, as well as nucleic acid molecules encoding basal endosperm transfer cell layer (BETL) proteins.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 5, 2014
    Assignee: Biogemma
    Inventors: Pascual Perez, José Gutierrez-Marcos, Hugh Dickinson
  • Patent number: 8795675
    Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: August 5, 2014
    Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
  • Patent number: 8796440
    Abstract: The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: August 5, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Feng Yao
  • Patent number: 8795965
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 5, 2014
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Publication number: 20140213779
    Abstract: The present invention relates to a system comprising a genetic construct a riboswitch operably linked to a regulatory sequence, and a second genetic construct a coding sequence whose expression is capable of being regulated by a gene product of the first construct. Also provided is a genetic construct comprising one or more riboswitches for regulation of gene expression, wherein preferably a spacer sequence is provided downstream of the riboswitch to enhance expression of a coding sequence which is operably linked to a riboswitch. Ligands, kits, methods, host cells and expression systems are also provided.
    Type: Application
    Filed: May 10, 2012
    Publication date: July 31, 2014
    Applicant: THE UNIVERSITY OF MANCHESTER
    Inventors: Neil Dixon, Jason Micklefield
  • Patent number: 8790896
    Abstract: The present invention relates to a method for increasing the expression of a protein in cells, preferably in eukaryotic cells, by reducing the number of RNase L cleavage sites in the coding and/or non-coding region of the nucleic acid sequence of said protein. Furthermore, it relates to nucleic acid sequences exhibiting a reduced number of RNase L cleavage sites as well as to the proteins translated from such sequences.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: July 29, 2014
    Assignees: King Faisal Specialist Hospital & Research Centre, Terramark Markencreation GmbH
    Inventor: Khalid S. Khabar
  • Patent number: 8791248
    Abstract: A method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: July 29, 2014
    Assignee: Kyoto University
    Inventors: Shinya Yamanaka, Michiyo Koyanagi
  • Patent number: 8791325
    Abstract: The invention provides for identification and use of certain chloroplast transit peptides for efficient processing and localization of dicamba monooxygenase (DMO) enzyme in transgenic plants. Methods for producing dicamba tolerant plants, methods for controlling weed growth, and methods for producing food, feed, and other products are also provided, as well as seed that confers tolerance to dicamba when it is applied pre- or post-emergence.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 29, 2014
    Assignee: Monsanto Technology LLC
    Inventors: Paul C. C. Feng, Marianne Malven, Stanislaw Flasinski
  • Patent number: 8791330
    Abstract: The present invention relates generally to an expression regulatory element operable in plants which includes oil palm, and in particular to an expression regulatory element operable selectively in the endosperm tissue of the plants. Said expression regulatory element comprises a sequence of nucleotides which specifically modulates the expression of a second nucleic acid molecule operably coupled to said expression regulatory element.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: July 29, 2014
    Assignee: Malaysian Palm Oil Board
    Inventors: Siti Nor Akmar Abdullah, Suan Choo Cheah, Nurniwalis Abd. Wahab